Navigation Links
Catabasis Closes $32.4 Million Series B Financing
Date:11/14/2013

CAMBRIDGE, Mass., Nov. 15, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced it has completed a $32.4 million Series B financing round led by new investor Lightstone Ventures. A leading public crossover fund and all current Catabasis investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures, also participated in the financing.

"This investment reflects our confidence in Catabasis' pipeline of SMART Linker conjugates as much as our belief in management's ability to successfully advance its clinical candidates," said Jean George, partner of Lightstone Ventures. "Catabasis has achieved a number of important milestones in the past year including positive data from Phase 1 studies of both CAT-2003 and CAT-1004. We look forward to working with the management team as they complete the ongoing Phase 2 trial for CAT-2003 and seek to advance the rest of the pipeline."

Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline.

"We are tremendously excited about the progress we've made with our pipeline thus far, having reported positive Phase 1 data for both CAT-2003 and CAT-1004 and having advanced CAT-2003 to Phase 2," said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis. "This financing enables Catabasis to continue to execute on the promise of its pipeline for dyslipidemias and diseases involving chronic inflammation." 

About CatabasisCatabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profile. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.

Please visit www.catabasis.com for more information.Media Contacts

Corporate ContactTony Russo, Ph.D.

Amy LynchMatt Middleman, M.D.

Catabasis Pharmaceuticals, Inc.Russo Partners

T: (617)-349-1971T: 212-845-4251

alynch@catabasis.comT: 212-845-4272tony.russo@russopartnersllc.commatt.middleman@russopartnersllc.com
'/>"/>

SOURCE Catabasis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
3. Catabasis Names Ian Sanderson Chief Financial Officer
4. Independa Closes Convertible Note Funding at $2.35 Million
5. Stereotaxis Closes $18.5 Million Private Placement Financings
6. Boston Scientific Closes Cameron Health Acquisition
7. C8 MediSensors Closes $19 million Preferred Stock Financing
8. Igenica Closes $33 Million in Series C Funding
9. BONESUPPORT Closes Second Tranche of Funding
10. PTC Therapeutics Closes $30 Million Financing
11. Chiasma Closes $38.5 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... -- US medical equipment and supply demand is forecast to ... Medical Equipment & Supplies: United States , a ... in demand for medical services – driven in large ... by gains in disposable personal income – will boost ... will also drive sales as providers and patients seek ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... 2017 Pace Analytical, a company of over 2,000 employees and a ... acquired ESC Lab Sciences, further solidifying their position as the top American owned ... ... CEO of Pace Analytical ... of Mt Juliet, TN , enhances Pace Analytical,s capability as ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... USHEALTH Group, Inc. ... the prestigious CEO World Awards®. The coveted annual CEO World Awards program encompasses ... case studies, corporate social responsibility, and milestones from every major industry in the ...
(Date:7/24/2017)... ... ... Engineers at the University of Maryland have invented an entirely new kind ... that the body uses. , In ordinary batteries the electrical energy, or current, ... the battery is generated by moving positive ions from one end to the other ...
(Date:7/24/2017)... Kansas City, MO (PRWEB) , ... July 24, 2017 , ... ... for the acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of ... an interim basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Cosmetic Town, an ... and the cosmetic surgeries they perform on a daily basis. , The new ... surgery procedures they specialize in at their practices. , When asked about the ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon ... for a unique opportunity that helps high school girls succeed in STEM programs ... Opportunities.” Horizon Goodwill will host over 20 high school girls at their ...
Breaking Medicine News(10 mins):